https://pressroom.prlog.org/naprx-cnpr/ NAPSRx Latest Press Releases https://www.prlog.org/12479445-regeneron-and-sanofis-cholesterol-treatment-praluent-gets-fda-approval.html The U.S. Food and Drug Administration has approved Praluent (alirocumab) Injection to treat high LDL Cholesterol in adult patients.Tue, 28 Jul 2015 20:08:08 GMT https://www.prlog.org/12478140-bms-gets-fda-breakthrough-therapy-designation-for-investigational-hiv-treatment.html The U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to Bristol-Myers Squibb’s investigational compound BMS-663068 when used in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection...Thu, 23 Jul 2015 18:44:45 GMT https://www.prlog.org/12477335-exelixis-announces-breakthrough-results-from-kidney-cancer-study-assessing-cometriq.html Exelixis, Inc. has announced positive top line results from METEOR, the pivotal phase 3 trial evaluating COMETRIQ® (cabozantinib) in comparison to everolimus in 658 patients with metastatic renal cell carcinoma (RCC) who have experienced disease...Tue, 21 Jul 2015 19:23:27 GMT https://www.prlog.org/12475180-fda-approves-rexulti-to-treat-depression-and-schizophrenia.html Otsuka Pharmaceuticals and Lundbeck have received approval from the U.S.Tue, 14 Jul 2015 17:50:05 GMT https://www.prlog.org/12473335-novartis-breakthrough-heart-failure-medicine-lcz696-now-called-entrestotm-receives-fda-approval.html The US Food and Drug Administration (FDA) has officially greenlighted Novartis’ heart failure drug Entresto(TM)  formerly known as LCZ696 to treat heart failure with reduced ejection fraction.Wed, 08 Jul 2015 15:12:11 GMT https://www.prlog.org/12470509-novartis-buys-spinifex-pharmaceuticals-acquiring-their-mid-stage-neuropathic-drug-ema401.html Novartis will acquire Spinifex Pharmaceuticals, a US and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain.Mon, 29 Jun 2015 19:14:03 GMT https://www.prlog.org/12469015-new-forecast-predicts-drug-sales-to-grow-nearly-five-percent-annually-for-the-pharmabiotech-sector.html According to the “EvaluatePharma World Preview 2015, Outlook to 2020” report, prescription sales are expected to increase 5 percent annually over the next five years across the United States  and Europe.Wed, 24 Jun 2015 15:15:18 GMT https://www.prlog.org/12468234-fda-approves-additional-indication-for-eisais-fycompa-for-epilepsy-patients.html The U.S. Food And Drug Administration (FDA) has approved Eisai’s antiepileptic agent Fycompa® (perampanel hydrate) to be used as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and...Mon, 22 Jun 2015 18:58:12 GMT https://www.prlog.org/12466945-napsrx-news-allergan-will-acquire-kythera-biopharmaceuticals.html Allergan plc has agreed to acquire KYTHERA Biopharmaceuticals, Inc for approximately $2.1 billion valued at $75 per KYTHERA share.Wed, 17 Jun 2015 18:57:35 GMT https://www.prlog.org/12464893-fda-committee-recommends-approval-of-praluent-injection-to-treat-hypercholesterolemia.html In a 13 to 3 vote, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S.Thu, 11 Jun 2015 14:16:57 GMT https://www.prlog.org/12463252-fda-panel-recommends-approval-of-sprout-pharmaceuticals-addyi-for-low-female-libido.html The U.S. Food and Drug Administration’s (FDA) meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee, and the Drug Safety and Risk Management Advisory Committee has decided to support the approval of the benefit/risk profile of Sprout...Fri, 05 Jun 2015 20:30:45 GMT https://www.prlog.org/12460917-rapamune-from-pfizer-is-the-first-fda-approved-treatment-for-lam-rare-progressive-lung-disease.html The U.S. Food and Drug Administration (FDA) has approved Pfizer’s RAPAMUNE® (sirolimus) making it the first approved therapy to treat lymphangioleiomyomatosis (LAM), a rare disease that affects the lungs, kidneys and the lymphatic system, which tends...Fri, 29 May 2015 19:40:23 GMT https://www.prlog.org/12460415-napsr-news-fda-approves-xifaxan-from-valeant-to-treat-ibs.html Valeant Pharmaceutical’s wholly owned subsidiary, Salix Pharmaceuticals, Inc received approval from the U.S. Food and Drug Administration (FDA) for Xifaxan® 550 mg to treat IBS-D (Irritable Bowel Syndrome with Diarrhea) in adults.Thu, 28 May 2015 14:58:38 GMT https://www.prlog.org/12458494-napsrx-news-johnson-johnson-janssen-intends-to-file-more-than-10-new-products-by-2019.html Johnson & Johnson (Janssen) plans to file regulatory approvals for 10 new products between 2014 and 2019, each with the potential to accumulate $1 billion in revenue plus 40 line extensions of existing and new medicines.Thu, 21 May 2015 20:46:57 GMT https://www.prlog.org/12457439-napsrx-news-endo-plans-to-expand-generics-business-by-acquiring-par-pharmaceuticals.html In a robust deal worth $8.05 billion, Endo Pharmaceuticals will acquire privately-held Par Pharmaceutical Holdings from TPG.Tue, 19 May 2015 15:47:47 GMT https://www.prlog.org/12455655-baxter-bioscience-acquires-oncaspar-portfolio-for-leukemia.html Baxter is ready to expand its oncology segment by acquiring Oncaspar® (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A for USD $900 million.Wed, 13 May 2015 17:10:45 GMT https://www.prlog.org/12454254-investigational-medicine-venetoclax-receives-breakthrough-therapy-designation-from-the-fda.html The investigational drug venetoclax has been granted Breakthrough Therapy Designation from the U.S.Fri, 08 May 2015 19:07:02 GMT https://www.prlog.org/12453423-napsr-news-teva-acquires-auspex-pharmaceuticals.html Teva Pharmaceuticals has acquired Auspex Pharmaceuticals, Inc for all of the outstanding shares of common stock of Auspex at $101.00 per share in cash, totaling approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity...Wed, 06 May 2015 19:11:44 GMT https://www.prlog.org/12453038-bayer-acquires-rights-to-develop-and-commercialize-isis-fxi-rx-to-prevent-thrombosis.html Isis Pharmaceuticals has entered into an agreement with Bayer Healthcare to commercialize and develop ISIS-FXIRx for the prevention of thrombosis.Tue, 05 May 2015 20:45:29 GMT https://www.prlog.org/12451529-napsrx-news-fda-approves-kybella-first-and-only-submental-contouring-injectable-drug.html On April 29, 2015, the U.S Food and Drug Administration (FDA) approved KYBELLA (deoxycholic acid) Injection manufactured by Kythera Biopharmaceuticals to improve Submental Fullness, or “Double Chin”.Thu, 30 Apr 2015 15:47:09 GMT https://www.prlog.org/12450167-napsr-news-eli-lillys-cyramza-gets-fourth-fda-approval.html Eli Lilly’s breakthrough cancer treatment CYRAMZA® (ramucirumab) has received another approval from the U.S Food and Drug Administration (FDA) making this the fourth approved indication for the treatment.Mon, 27 Apr 2015 18:07:25 GMT https://www.prlog.org/12449506-fda-grants-priority-review-for-abbvies-investigational-therapy-to-treat-gt4-hep-virus.html The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted priority review for Abbvie’s all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with...Fri, 24 Apr 2015 16:38:29 GMT https://www.prlog.org/12448245-pfizer-receives-fda-breakthrough-therapy-designation-for-xalkori-to-treat-ros1-positive-nsclc.html Pfizer has received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for  XALKORI® (crizotinib) to potentially treat patients with ROS1-positive non-small cell lung cancer (NSCLC).Tue, 21 Apr 2015 18:30:07 GMT https://www.prlog.org/12446679-amgens-corlanor-is-the-first-chf-medicine-to-be-approved-by-the-fda-in-nearly-decade.html The U.S. Food and Drug Administration (FDA) has approved Amgen’s Corlanor® (ivabradine) to treat chronic heart failure.Thu, 16 Apr 2015 15:48:26 GMT https://www.prlog.org/12445378-horizon-gets-fda-fast-track-designation-for-actimmune-to-treat-friedreichs-ataxia.html Horizon Pharma plc has announced that ACTIMMUNE® has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA), to treat Friedreich's ataxia (FA), a degenerative neuro-muscular disorder.Mon, 13 Apr 2015 19:17:04 GMT https://www.prlog.org/12443541-bms-has-joined-forces-with-uniqure-to-develop-gene-therapies-for-cardiovascular-diseases.html Bristol-Myers Squibb (BMS) will get exclusive access to uniQure’s gene technology platform based on a strategic collaboration between both companies to identify multiple targets in cardiovascular diseases.Tue, 07 Apr 2015 19:01:51 GMT https://www.prlog.org/12441705-napsr-news-fda-approves-tevas-proair-respiclick.html ProAir® RespiClick is the first Breath-Actuated Dry-Powder Short-Acting Beta-Agonist (SABA) Inhaler to be approved by the FDA.Wed, 01 Apr 2015 16:29:11 GMT https://www.prlog.org/12441204-fda-approves-jadenu-from-novartis-to-treat-chronic-iron-overload.html Jadenu, a new formulation of Exjade (deferasirox) is a simplified daily treatment, administered to patients with chronic iron overload.Tue, 31 Mar 2015 15:03:13 GMT https://www.prlog.org/12440113-napsr-news-regenerons-eylea-receives-expanded-approval-from-the-fda.html The U.S. Food and Drug Administration (FDA) has officially greenlighted Regeneron’s EYLEA® (aflibercept) Injection to treat Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME) which marks the fourth approved indication for the drug in...Fri, 27 Mar 2015 15:48:50 GMT https://www.prlog.org/12439425-napsr-news-astrazeneca-and-harvard-team-up-for-diabetes-research.html AstraZeneca will enter into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI)  in order to acclimatize a technique for the creation of human beta cells from stem cells for use in screens of AstraZeneca’s compound...Wed, 25 Mar 2015 19:48:41 GMT https://www.prlog.org/12437622-napsr-news-daiichi-sankyo-will-collaborate-with-astrazeneca-in-commercializing-movantik-in-the-us.html Daiichi Sankyo, Inc has partnered with AstraZeneca to co-commercialize MOVANTIK™ (naloxegol) in the US which is a once-daily oral PAMORA specifically designed for the treatment of OIC in adult patients with chronic non-cancer pain.Fri, 20 Mar 2015 15:33:09 GMT https://www.prlog.org/12437252-eli-lilly-inks-deal-with-hanmi-pharmaceutical-to-develop-experimental-immunological-therapy.html Eli Lilly has entered into an exclusive license agreement with Hanmi Pharmaceutical Co., Ltd. to develop and commercialize Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases.Thu, 19 Mar 2015 16:37:08 GMT https://www.prlog.org/12436485-napsrx-news-new-global-fund-established-for-dementia-research.html The Dementia Discovery Fund has been established by the UK government to fuel research and development for Dementia which pose a serious threat to public health and healthcare systems globally according to the World Health Organization.Tue, 17 Mar 2015 21:02:40 GMT https://www.prlog.org/12435327-napsrx-news-bayer-aims-to-expand-life-science-businesses.html Bayer HealthCare striving for strong sales and margin growth through 2017!Fri, 13 Mar 2015 20:38:41 GMT https://www.prlog.org/12433815-napsrx-news-fda-approves-unituxin-to-treat-pediatric-high-risk-neuroblastoma.html The U.S. Food and Drug Administration (FDA) has approved Unituxin (dinutuximab) from the United Therapeutics Corporation as a part of first-line therapy for pediatric patients with high-risk neuroblastoma.Tue, 10 Mar 2015 16:11:37 GMT https://www.prlog.org/12432247-napsrx-news-abbvie-will-acquire-pharmacyclics-for-an-astounding-21-billion.html In an effort to expand their presence in the oncology market and expand their already resilient pipeline, Abbvie will acquire Pharmacyclics  including its blockbuster product Imbruvica, a first class BTK inhibitor approved for hematologic...Thu, 05 Mar 2015 15:33:07 GMT https://www.prlog.org/12431295-napsrx-news-shire-submits-nda-for-new-eye-treatment-lifitegrast.html Shire has submitted a New Drug Application (NDA) with the U. S. Food and Drug Administration for a novel small-molecule integrin inhibitor called Lifitegrast to treat dry eye disease symptoms in adults.Tue, 03 Mar 2015 15:22:48 GMT https://www.prlog.org/12429691-napsr-news-sanofi-receives-fda-approval-for-once-daily-basal-insulin-toujeo.html The U.S. Food and Drug Administration (FDA) has approved Sanofi’s Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, intended to improve the glycemic index in adults living with type 1 and type 2...Thu, 26 Feb 2015 15:14:42 GMT https://www.prlog.org/12428297-napsr-news-valeant-will-acquire-salix-pharmaceuticals.html Valeant Pharmaceuticals will enter into a definitive agreement to acquire Salix Pharmaceuticals for $158.00 per share in cash totaling approximately $14.5 billion in enterprise value.Mon, 23 Feb 2015 17:53:04 GMT https://www.prlog.org/12426831-napsrx-reviews-the-benefits-of-becoming-pharmaceutical-sales-rep.html There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.Wed, 18 Feb 2015 20:27:37 GMT https://www.prlog.org/12426331-novartis-breakthrough-heart-failure-medicine-lcz696-receives-fda-priority-review.html The U.S. Food and Drug Administration (FDA) has granted priority review for Novartis’ investigational medicine, LCZ69 to treat heart failure with reduced ejection fraction (HFrEF).Tue, 17 Feb 2015 19:10:46 GMT https://www.prlog.org/12425364-fda-approves-eisais-banzel-as-an-adjunctive-treatment-of-seizures-in-kids-age-14-with-lgs.html The U.S. Food and Drug Administration (FDA) approved supplemental New Drug Application (sNDA) for Eisai’s BANZEL®(rufinamide) to be used as an adjunctive treatment of seizures in pediatric patients one to four years old with Lennox-Gastaut Syndrome...Fri, 13 Feb 2015 19:39:57 GMT https://www.prlog.org/12424934-napsrx-news-genzyme-inks-gene-therapy-deal-with-voyager-therapeutics.html Voyager Therapeutics and Genzyme, a Sanofi company, have entered into a  collaborative deal to develop treatments aimed at combatting fatal and debilitating diseases affecting the central nervous system (CNS).Thu, 12 Feb 2015 18:15:51 GMT https://www.prlog.org/12423489-roches-lucentis-gets-expanded-approval-from-the-fda-to-treat-diabetic-retinopathy.html The U.S. Food and Drug Administration has approved Roche’s Lucentis for the treatment of diabetic retinopathy (DR), in people with diabetic macular edema (DME).Mon, 09 Feb 2015 19:33:40 GMT https://www.prlog.org/12422346-napsr-news-pfizer-will-acquire-hospira-for-17-billion.html Pfizer Inc has announced their plans to acquire Hospira, Inc in a deal worth approximately $17 billion dollars. Hospira is the world’s leading provider in injectable drugs, infusion technologies and biosimilars.Thu, 05 Feb 2015 16:45:18 GMT https://www.prlog.org/12421335-novartis-receives-fda-approval-for-eye-drop-solution.html Novartis’ eye care division, Alcon received approval from the U.S. Food and Drug Administration (FDA) for their ophthalmic solution Pazeo 0.7% to treat ocular itching associated with allergic conjunctivitis.Tue, 03 Feb 2015 16:05:40 GMT https://www.prlog.org/12420233-fda-approves-imbruvica-to-treat-rare-form-of-non-hodgkin-lymphoma.html J & J's Imbruvica has been cleared for expanded approval by the U.S. Food and Drug Administration to treat patients with Waldenström’s macroglobulinemia (WM), a rare cancer that originates in the body’s immune system.Fri, 30 Jan 2015 18:40:21 GMT https://www.prlog.org/12419440-roches-pharmaceutical-unit-posts-strong-sales-for-2014.html Roche’s pharmaceutical division maintained solid sales for the 2014 year as the company revealed a 4% increase in pharmaceutical sales which were primarily driven by medicines in the oncology and immunology segment.Wed, 28 Jan 2015 21:23:36 GMT https://www.prlog.org/12418352-novartis-receives-fda-approval-for-new-meningitis-vaccine.html Novartis’ new vaccine Bexsero® has been granted accelerated approval by the U.S. Food and Drug Administartion (FDA) for the prevention of bacterial meningitis B in adolescents and young adults from 10 years through 25 years of age.Mon, 26 Jan 2015 18:43:53 GMT https://www.prlog.org/12417733-fda-anti-infective-drug-panel-recommends-approval-of-astellas-new-antifungal-treatment.html The U.S. Food and Drug Administration's (FDA) Anti-infective Drugs Advisory Committee reached a unanimous decision to recommend approval of Astellas’ CRESEMBA® (isavuconazonium) an investigational treatment for mucormycosis (also known as...Fri, 23 Jan 2015 19:39:25 GMT